The scale of the clinical problem is difficult to overstate. Systematic reviews and meta-analyses cited by the authors show that comorbid substance use is strikingly common among people with schizophrenia spectrum disorders, and that a large proportion of people accessing mental health treatment report problematic alcohol or other drug use. These overlapping conditions are associated with poorer treatment outcomes, higher rates of relapse and hospitalization, and markedly elevated risks of premature death, particularly among people who also experience co-occurring social disadvantage such as homelessness or poverty. Genetic and epidemiological research, including Mendelian randomization studies, further suggests that the relationship between mental health and substance use is bidirectional and deeply entangled, meaning that treating one condition in isolation from the other is scientifically as well as clinically questionable.

Yet the organizational reality of care remains stubbornly split. Mental health services and addiction services grew up as separate professional territories, with distinct funding streams, legal frameworks, data systems, and diagnostic cultures. Studies assessing programs across multiple state systems in the United States have found that only a minority of mental health or addiction treatment services possess genuine dual diagnosis capability, and a systematic review of the organization of community health services for dual diagnosis found that integrated models remain the exception rather than the rule internationally. Even where integrated dual diagnosis treatment programs exist, evidence of their effectiveness is mixed, and a recent scoping review of non-pharmacological components of integrated treatment highlights how much uncertainty still surrounds what actually works, for whom, and why.

The Norwegian team’s central theoretical move is to argue that fragmentation and continuity should not be understood simply as design failures or resource problems, but as emergent outcomes of interacting stigma- and recognition-related processes operating at three distinct levels: the macro level of institutions, the meso level of organizations, and the micro level of relationships. Stigma theory, from Erving Goffman’s classic account of spoiled identity through Bruce Link and Jo Phelan’s influential conceptualization of stigma as a cascade of labeling, stereotyping, separation, status loss, and discrimination, has long described how people with substance use disorders are devalued even within health care itself. Research consistently shows that health professionals hold stigmatizing attitudes toward patients with substance use problems, and that these attitudes shape clinical decisions, treatment engagement, and the quality of care delivered. Philip Corrigan and colleagues extended this analysis to structural levels of stigma, showing how institutional policies and resource allocations can encode discrimination without any individual acting maliciously.

What existing multilevel stigma perspectives explain well, the authors contend, is exclusion—how people with dual diagnosis get pushed to the margins of systems that quietly signal they belong elsewhere. What they explain poorly is the reverse phenomenon: how continuity of care is actually established and sustained across interconnected contexts. This is where recognition theory enters. Drawing on Axel Honneth’s account of the struggle for recognition, along with the political-philosophical exchange between Honneth and Nancy Fraser, the framework treats recognition not merely as a warm interpersonal quality but as a normative principle with structural teeth. Recognition, in this account, involves acknowledging a person as a legitimate participant with claims that deserve response—as a subject of rights, as a bearer of needs worth taking seriously, and as a contributor whose own experience and agency matter to the course of recovery.

The framework’s ecological scaffolding comes from Urie Bronfenbrenner’s ecological systems theory, which understands human development as shaped by nested systems ranging from immediate interpersonal settings to broad institutional and cultural contexts. The authors adopt and adapt this multilevel architecture for health services research, treating macro, meso, and micro levels as dynamically interconnected rather than neatly nested. At the macro level, institutional commitments—legislation, professional jurisdictions, funding rules, and diagnostic categories—determine whether dual diagnosis is officially recognized as a legitimate object of care at all. At the meso level, organizational arrangements—team structures, documentation systems, referral pathways, and professional cultures—determine whether that commitment translates into services that can actually respond. At the micro level, relational practices—the quality of the encounter between clinician and patient—determine whether the person experiences being seen as a whole human being rather than as a diagnostic fragment.

Crucially, the framework proposes that these levels must be aligned for continuity to emerge. An institution can formally mandate integrated care while organizational boundaries and professional territoriality quietly undermine it; clinicians can be individually compassionate while documentation systems and funding incentives force them to treat one condition at a time. Misalignment across levels produces what patients experience as bouncing between services, repeating their stories to strangers, being discharged from one system because their other condition is “not our responsibility,” and ultimately disengaging from help altogether. Alignment, by contrast, allows recognition to function as a coordinating principle: institutional commitments legitimize the whole person’s needs, organizational arrangements make coordinated responses routine, and relational practices convey dignity and trust in every individual encounter. Fragmentation and continuity are thus reframed as emergent, system-level properties rather than local failings.

This reframing has significant practical implications. Anti-stigma interventions in health care have historically focused on changing individual attitudes through education or contact, with systematic reviews showing modest and uneven effects. A recognition-based multilevel framework suggests why: attitudinal change at the micro level cannot survive contact with structural stigma at the meso and macro levels unless those levels are addressed simultaneously. Realist reviews of interventions to dismantle structural stigma in health care settings point in a similar direction, emphasizing changes to policies, practices, and organizational cultures rather than hearts and minds alone. The Norwegian framework provides the theoretical vocabulary for this systems approach, suggesting that policy makers and service leaders should audit not only whether integrated care is mandated, but whether the entire chain—from legislation to documentation templates to the tone of the first clinical meeting—transmits recognition consistently.

The framework also resonates with recovery-oriented mental health research. Qualitative studies of inpatient experience show that being recognized as a whole person is among the most therapeutically powerful elements of care, and influential conceptual work on personal recovery identifies the rebuilding of a positive identity and meaningful social roles as central to recovery processes. Trauma-informed care movements similarly argue that relationships, not procedures, are the active ingredient of effective mental health services. By grounding these insights in formal theory, Dale and colleagues elevate them from clinical wisdom to testable system-level propositions: that services aligned around recognition should show greater continuity, participation, legitimacy, collaboration, and trust—the five outcomes the framework explicitly names.

The authors are candid about the conceptual nature of their contribution. The article involves no new empirical data; instead, it performs a conceptual synthesis of empirical and theoretical literature, and the authors note that no datasets were generated or analyzed. Its value lies in providing an analytical lens rather than an intervention manual. Future research, they imply, should use the framework to trace precisely where recognition breaks down in real care pathways—whether in funding formulas, interprofessional hierarchies, electronic records that cannot capture dual diagnoses, or the micro-politics of clinical encounters—and to evaluate whether deliberately aligning recognition-supporting conditions across levels improves continuity and outcomes for people with dual diagnosis.

For the millions of people worldwide navigating life with both a mental health condition and a substance use disorder, the message is both sobering and hopeful. Sobering, because the framework makes clear that fragmented care is not an accident but the predictable output of misaligned systems saturated with stigma at every level. Hopeful, because it identifies a concrete lever: recognition, deliberately engineered into institutions, organizations, and relationships alike, could be the principle through which the long-promised integration of mental health and addiction care finally becomes a lived reality rather than a policy slogan.

The study leveraged comprehensive prescription registry data spanning several years, comparing psychotropic medication prescribing patterns before and during the COVID-19 pandemic among individuals diagnosed with dual diagnoses—severe mental illnesses alongside substance use disorders. Severe mental illnesses, often encompassing conditions such as schizophrenia, bipolar disorder, and major depressive disorder, already pose significant challenges in terms of effective management. When combined with substance use disorders, treatment complexity amplifies, and the exigencies of pandemic restrictions only intensified these challenges. The findings of the study underscore not only changes in drug prescription rates but also hint at broader systemic adaptations in healthcare delivery amid public health crises.

One of the most striking findings from this Norwegian study is the nuanced shift in different classes of psychotropic medications. While the overall prescription volume saw fluctuations, specific drug categories exhibited contrasting trends. For instance, there was a noticeable increase in prescriptions for anxiolytics and hypnotics during the pandemic period. This pattern suggests a heightened incidence of anxiety and sleep disturbances, which aligns with widespread reports of pandemic-related stress, social isolation, and uncertainty. These increased prescriptions highlight how healthcare providers may have responded to escalating psychological distress by intensifying pharmacological interventions aimed at symptom relief.

Conversely, the study noted a relative decrease or stabilization in prescriptions for antipsychotics and mood stabilizers, which are traditionally used for managing core symptoms of severe mental illnesses. This observation may be attributed to various factors including reduced healthcare accessibility, modifications in treatment protocols, or changes in patient engagement due to lockdowns and mobility restrictions. Indeed, severe mental illness management often necessitates careful monitoring and follow-up, something that proved challenging during periods of pandemic-induced social distancing. Such findings emphasize the delicate balance clinicians must strike between managing acute psychiatric symptoms and mitigating risks associated with pandemic-related systemic disruptions.

The implications of altered prescribing patterns extend beyond immediate clinical outcomes. Psychotropic drugs carry risks of side effects, dependency, and interactions, especially in populations with concurrent substance use disorders. Increased medication use, particularly of anxiolytics such as benzodiazepines, raises critical questions about potential escalation of substance dependence, as these drugs themselves can be prone to misuse. This highlights the tension between rapidly addressing acute psychological distress during crises and ensuring long-term safety and efficacy in a population vulnerable to polypharmacy and addiction.

Furthermore, the Norwegian registry data revealed demographic and regional disparities in prescription changes, painting a complex picture of healthcare equity during the pandemic. Individuals living in urban areas, where COVID-19 incidence was higher and restrictions more stringent, exhibited different trends compared to those in rural regions. Younger patients tended to show greater increases in psychotropic prescriptions, a finding that aligns with broader global research underscoring the pandemic’s disproportionate psychological impact on youth. These nuances emphasize the importance of contextual factors when interpreting national prescription data, suggesting that public health responses must be tailored to diverse patient needs and local realities.

The study’s methodology deserves particular note for its rigor and scope. By utilizing nationwide registry data, the researchers captured real-world prescribing behaviors across a large and clinically heterogeneous population. This approach circumvents limitations of smaller clinical samples and provides a robust lens into population-level trends. Such register-based studies exemplify the power of centralized health data infrastructure in informing public health responses, especially in times of widespread crisis. Norway’s comprehensive pharmaceutical registries have set a benchmark for other countries seeking to understand medication use patterns and optimize mental health care delivery.

In addition to quantitative prescription data, the study situates its findings within a broader clinical and societal context. The pandemic led to massive disruptions in outpatient psychiatric services, with many consultations shifting to telehealth platforms. While telemedicine proved vital in maintaining continuity of care, it also introduced challenges in accurate diagnosis and medication management, especially for complex dual diagnosis patients. The Norwegian study indirectly reflects these challenges—variations in prescribing may partly represent clinician hesitancy or altered clinical judgment under telehealth constraints.

Moreover, the research underscores the interplay between mental health prescribing and substance use treatment services. In Norway, specialized addiction services were also pressured by pandemic restrictions, potentially impacting the integrated management of patients with co-occurring disorders. Interruptions in psychosocial treatments may have contributed to greater reliance on pharmacological approaches. This trend calls for urgent consideration of how to maintain multi-modal therapies balancing medication, counseling, and harm reduction strategies during emergencies.

The study’s findings also offer critical policy implications. With evidence of pandemic-driven shifts in psychotropic prescriptions, health authorities must consider strategic planning for medication supply chains, clinician training, and patient monitoring to mitigate risks such as medication shortages, inappropriate prescribing, and drug interactions. It also highlights the urgent need to strengthen mental health and addiction services’ resilience—ensuring that vulnerable populations do not experience diminished care quality during crises.

This Norwegian nationwide investigation opens avenues for future research to further dissect the consequences of altered prescribing trends. Longitudinal studies assessing clinical outcomes such as relapse rates, hospitalization, and functional status will be vital to understand the real-world impact of these trends. Additionally, qualitative research exploring patient and clinician experiences can deepen insights into barriers and facilitators influencing treatment decisions in pandemic contexts.

Beyond Norway, these findings resonate globally, as healthcare systems worldwide grappled with the pandemic’s psychological toll. The study provides a valuable template for other nations to analyze their own data, fostering international comparisons that can inform best practices. The lessons learned can drive innovations in remote care, integrated dual diagnosis treatment, and real-time pharmacoepidemiological surveillance methods to better prepare for future public health emergencies.

In sum, the COVID-19 pandemic represented an unprecedented natural experiment, reshaping mental health treatment paradigms overnight. This innovative nationwide study from Norway offers compelling evidence of how psychotropic drug prescriptions adapted in response to new clinical, societal, and systemic pressures, especially among individuals burdened by severe mental illness and substance use disorders. The findings illuminate a complex interplay of increased anxiety symptom management, healthcare access challenges, and demographic disparities, all converging to reshape pharmacological treatment landscapes. Importantly, these insights provide a crucial foundation for clinicians, researchers, and policymakers striving to optimize mental health care delivery in an era of ongoing uncertainty.

As we move forward, integrating these epidemiological insights with advanced digital health tools and personalized medicine approaches holds promise for more responsive and resilient mental health systems. By learning from the pandemic’s lessons, there is hope to build more adaptive and patient-centered care models that can withstand future crises while minimizing harm and maximizing recovery for those navigating the dual challenges of severe mental illness and substance use.

Subject of Research: The study investigates changes in prescription patterns of psychotropic drugs among individuals with concurrent severe mental illnesses and substance use disorders, comparing periods before and during the COVID-19 pandemic in Norway.

Article Title: Prescription of Psychotropic Drugs in Persons With Concurrent Severe Mental Illness and Substance Use Disorders Before and During the COVID-19 Pandemic in Norway — A Nationwide Register Study.

Article References:
Leonhardt, M., Bramness, J.G., Hartz, I. et al. Prescription of Psychotropic Drugs in Persons With Concurrent Severe Mental Illness and Substance Use Disorders Before and During the COVID-19 Pandemic in Norway — A Nationwide Register Study. Int J Ment Health Addiction (2025). https://doi.org/10.1007/s11469-025-01551-w

Image Credits: AI Generated

DOI: https://doi.org/10.1007/s11469-025-01551-w